# US Ankylosing Spondylitis Treatment Market > US Ankylosing Spondylitis Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Non-Steroidal Anti-Inflammatory Drugs, Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Analgesics, Disease Modifying Anti-Rheumatic Drugs), By Route of Administration (Oral, Injectable, Topical), By Patient Type (Adults, Pediatric) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.9% - **2024:** $ 1,211.62 Million - **2025:** $ 1,270.99 Million - **2035:** $ 2,051.07 Million - **Key Players:** AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Novartis (CH), Pfizer (US), Roche (CH), Sanofi (FR), UCB (BE) **Report ID:** MRFR/HC/14347-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-ankylosing-spondylitis-treatment-market-15874 --- ## Market Summary ## **US Ankylosing Spondylitis Treatment Market Overview** As per MRFR analysis, the US Ankylosing Spondylitis Treatment Market Size was estimated at 0.99 (USD Billion) in 2023. The US Ankylosing Spondylitis Treatment Market Industry is expected to grow from 1.03(USD Billion) in 2024 to 1.72 (USD Billion) by 2035. The US Ankylosing Spondylitis Treatment Market CAGR (growth rate) is expected to be around 4.753% during the forecast period (2025 - 2035). ### **Key US Ankylosing Spondylitis Treatment Market Trends Highlighted** The US Ankylosing Spondylitis Treatment Market is experiencing significant transformation driven by various key market drivers. An increase in the prevalence of ankylosing spondylitis, especially among younger populations, has led to a growing demand for effective treatment options. Advances in biologics and target-specific therapies are enhancing treatment outcomes, prompting healthcare providers to adopt innovative therapies. Furthermore, the rise in patient awareness regarding the disease and available treatments is encouraging early diagnosis and intervention, ultimately improving patient management. There are notable opportunities in the development of personalized medicine that can cater to individual patient needs based on genetic, environmental, and lifestyle factors.With the shifting focus towards patient-centric approaches in treatment, pharmaceutical companies can explore customized therapies that offer improved efficacy and safety profiles. Additionally, there is potential in expanding telehealth services, allowing patients greater access to healthcare professionals and treatment without the need for in-person visits, particularly beneficial for those living in rural areas. Recent trends in the US show a growing interest in holistic approaches to managing ankylosing spondylitis, incorporating physical therapy, lifestyle modifications, and dietary changes alongside traditional medicine. The emphasis on integrated care is reshaping treatment paradigms, as healthcare systems strive to provide comprehensive care that addresses both the physical and mental health aspects of the disease.Moreover, ongoing clinical trials and research into new treatment modalities are vital to expanding the therapeutic options available in the market, ensuring that patients have access to the latest advancements in care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Ankylosing Spondylitis Treatment Market Drivers** ### **Increasing Prevalence of Ankylosing Spondylitis** The US Ankylosing Spondylitis Treatment Market Industry is witnessing an increasing prevalence of ankylosing spondylitis, which is a chronic inflammatory disease affecting the spine and pelvis. According to the National Institutes of Health, approximately 0.1% to 0.5% of the US population is affected by ankylosing spondylitis, with cases rising due to improved diagnostic criteria and awareness. Furthermore, the Arthritis Foundation estimates that around 80% of individuals diagnosed with ankylosing spondylitis are between the ages of 20 and 40, indicating a younger patient demographic that is likely to seek treatment options actively.This growing patient base is expected to significantly drive the US Ankylosing Spondylitis Treatment Market as more individuals require effective treatment solutions to manage their condition. ### **Advancements in Biologics and Pharmaceuticals** Ongoing Research and Development in biologics and new pharmaceuticals have been pivotal in expanding treatment options for ankylosing spondylitis. Since the approval of anti-tumor necrosis factor (anti-TNF) medications in the early 2000s, the US market has seen a substantial increase in the availability of innovative therapies that significantly improve patient outcomes. For instance, the US Food and Drug Administration has approved several new biologic agents in recent years, enhancing the treatment landscape for ankylosing spondylitis.This surge in product offerings allows healthcare providers to personalize treatment strategies, thus improving patient compliance and outcomes, which is a crucial driver for the growth of the US Ankylosing Spondylitis Treatment Market. ### **Growing Geriatric Population** The increasing geriatric population in the United States is a significant driver for the US Ankylosing Spondylitis Treatment Market Industry. According to the United States Census Bureau, by 2030, approximately 20% of the US population will be aged 65 and older. The aging population is more susceptible to chronic conditions, including ankylosing spondylitis, which may lead to higher demand for treatment. Moreover, older patients typically have more complex healthcare needs, which can lead to a greater reliance on specialized treatment options.With healthcare reforms focusing on improving care for the elderly, this demographic trend will likely boost the demand for effective ankylosing spondylitis therapies in the US market. ## **US Ankylosing Spondylitis Treatment Market Segment Insights** ### **Ankylosing Spondylitis Treatment Market Treatment Type Insights** The Treatment Type segment for the US Ankylosing Spondylitis Treatment Market encompasses a diverse array of therapeutic options aimed at managing the symptoms and progression of the disease. As per the latest market statistics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have historically held a pivotal role in addressing pain and inflammation, essentially enhancing patients' quality of life. These medications are often the first line of treatment, and their widespread utilization speaks to the ongoing demand for effective pain management solutions within the patient population. Tumor Necrosis Factor Inhibitors, known for their ability to target underlying inflammatory processes, represent a significant advancement in Ankylosing Spondylitis treatment. This class of medications has shown remarkable efficiency in reducing disease activity and halting structural damage, thereby offering hope to many patients struggling with the debilitating effects of the condition. Interleukin Inhibitors, another emerging category within this treatment segment, are gaining traction due to their novel mechanisms of action. These biologics focus on specific pathways of inflammation, contributing to improved outcomes for patients who may not respond adequately to traditional therapies, thereby highlighting the importance of personalized treatment approaches. Additionally, Analgesics remain a crucial component of pain management strategies, often utilized in conjunction with other therapies to alleviate discomfort associated with Ankylosing Spondylitis. Furthermore, Disease Modifying Anti-Rheumatic Drugs (DMARDs) add another layer of treatment complexity, as they are particularly relevant for patients with more severe disease manifestations. This multifaceted segmentation underscores the opportunities within the US market to cater to varying patient needs and responses, ensuring that healthcare providers can adopt tailored treatment regimens. As the demographic and prevalence statistics for Ankylosing Spondylitis in the US indicate a steadily increasing patient population, the Treatment Type segment is poised for continued evolution and growth, supported by ongoing research, development initiatives, and the integration of innovative therapeutic modalities aimed at improving patient outcomes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Ankylosing Spondylitis Treatment Market Route of Administration Insights** The Route of Administration segment in the US Ankylosing Spondylitis Treatment Market plays a crucial role in shaping treatment efficacy and patient compliance. Currently, the market embraces diverse methods including Oral, Injectable, and Topical options, each catering to specific patient needs and preferences. Oral administration is often preferred for its convenience, allowing patients to incorporate medication seamlessly into their daily routines. Injectable treatments, on the other hand, typically provide faster relief and are often utilized for more severe cases, contributing to a significant portion of the treatment landscape.Topical treatments offer localized relief, appealing to patients seeking targeted therapy without systemic side effects. The increasing prevalence of Ankylosing Spondylitis in the US, combined with advancements in drug delivery systems, is driving innovations in each administration route. Challenges such as patient accessibility and variability in drug response necessitate ongoing Research and Development efforts. Moreover, healthcare professionals are focused on educating patients about the best administration methods to enhance treatment adherence and outcomes.As patient-centered care becomes a focal point in the healthcare industry, addressing the unique needs posed by different administration routes is vital for optimizing the US Ankylosing Spondylitis Treatment Market statistics and enhancing overall market growth. ### **Ankylosing Spondylitis Treatment Market Patient Type Insights** The Patient Type segment of the US Ankylosing Spondylitis Treatment Market represents a critical area of focus, encompassing both adults and pediatric patients. Adults are significantly impacted by ankylosing spondylitis, as the disease commonly manifests in early adulthood, leading to long-term implications for their quality of life and productivity. This population faces challenges that influence treatment approaches, making it essential for the market to develop tailored therapies that consider the unique needs of adults. Meanwhile, the pediatric segment is important as early diagnosis and intervention can greatly improve patient outcomes and manage disease progression effectively. The focus on young patients also illuminates opportunities for Research and Development in pediatric formulations of treatments designed specifically to accommodate growth and development. Overall, the demographic distribution within this segment reflects a substantial patient population that drives continued innovation and investment in the US Ankylosing Spondylitis Treatment Market, underscoring the need for effective treatment strategies that cater to both age groups. As such, addressing the nuances of these patient types is vital for ensuring comprehensive care and improving overall health outcomes within the US healthcare system. ### **Ankylosing Spondylitis Treatment Market Distribution Channel Insights** The Distribution Channel of the US Ankylosing Spondylitis Treatment Market plays a critical role in ensuring patients have access to effective therapies. Hospital pharmacies typically offer personalized services, such as medication management and monitoring, which are essential for patients diagnosed with Ankylosing Spondylitis. These pharmacies are often preferred by healthcare providers due to their ability to facilitate immediate access to specialized treatments in clinical settings. Retail pharmacies, on the other hand, account for a significant portion of the market by providing convenient access to a wider patient base, including those in rural areas. These pharmacies often promote patient education, which can increase adherence to treatment regimens. Meanwhile, the rise of online pharmacies represents a transformative trend, offering patients the flexibility to order medications from home, especially crucial for those with mobility challenges. This channel is gaining traction due to its convenience and the potential for cost savings, thereby catering to the evolving preferences of patients. The combination of these distribution channels underscores the importance of accessibility and patient care in the US Ankylosing Spondylitis Treatment Market, supporting ongoing trends in health service delivery and consumer behavior. ## **US Ankylosing Spondylitis Treatment Market Key Players and Competitive Insights** The US Ankylosing Spondylitis Treatment Market features a dynamic competitive landscape characterized by the presence of established pharmaceutical companies, innovative biotech firms, and a growing emphasis on personalized medicine. Driven by increasing awareness regarding the disease, the quest for effective treatment options, and advancements in medical research, the market demonstrates a solid potential for growth. Companies are actively investing in research and development to discover and commercialize new therapies, presenting an intensely competitive environment. Collaboration among industry stakeholders, such as partnerships between pharmaceutical companies and research institutions, further enhances the innovation ecosystem aimed at improving patient outcomes in ankylosing spondylitis. Celgene holds a significant position within the US Ankylosing Spondylitis Treatment Market, leveraging its strong research capabilities and expansive product portfolio. The company is known for its commitment to addressing unmet medical needs in inflammatory conditions, allowing it to enhance its market presence effectively. Celgene exhibits a range of strengths, including a robust pipeline of innovative therapeutic options and a solid reputation for safety and efficacy in its offerings. The company’s focus on clinical trials and collaboration with healthcare professionals has also contributed to its credibility and acceptance in the market, positioning it favorably among patients and prescribers alike. Novartis is another key player in the US Ankylosing Spondylitis Treatment Market, recognized for its comprehensive approach to developing cutting-edge therapies. The company offers a variety of key products and services targeting ankylosing spondylitis and has established a significant market presence through its well-regarded research and development initiatives. Novartis stands out with its strengths in immunology, delivering innovative treatments that improve the quality of life for patients. The company actively pursues mergers and acquisitions to enhance its portfolio and leverage synergistic opportunities, enabling it to stay ahead in the competitive landscape. Its strategic focus on innovation, patient-centric solutions, and a commitment to addressing the complexities of ankylosing spondylitis positions Novartis as a trusted partner within the US healthcare ecosystem. ### **Key Companies in the US Ankylosing Spondylitis Treatment Market Include** ## **US Ankylosing Spondylitis Treatment Market Industry Developments** The US Ankylosing Spondylitis Treatment Market has recently seen significant developments, particularly surrounding new therapeutic options and competitive strategies among key players like Celgene, Novartis, Takeda, Merck, Eli Lilly, Bristol Myers Squibb, Gilead Sciences, Sandoz, Pfizer, Amgen, AbbVie, Roche, Sanofi, Johnson and Johnson, and UCB. In September 2023, Eli Lilly announced promising results from a clinical trial on a novel monoclonal antibody aimed at improving patient outcomes, indicating strong growth potential for their treatment pipeline. Notably, in July 2023, AbbVie acquired an innovative biotech firm to enhance its Research and Development capabilities in inflammatory diseases, reflecting strategic moves to solidify their market position. Market valuation for Ankylosing Spondylitis treatments is projected to grow significantly, driven by an increasing prevalence of the disease among the US population and advancements in biological therapies. The integration of biosimilars into treatment protocols is also on the rise, as seen with Sandoz and Pfizer, aiming to make treatments more accessible. Over the last few years, robust investment in biologics and targeted therapies has transformed the treatment landscape, aligning with the growing need for effective solutions in managing Ankylosing Spondylitis. ## **US Ankylosing Spondylitis Treatment Market Segmentation Insights** ### **Ankylosing Spondylitis Treatment Market Treatment Type Outlook** ### **Ankylosing Spondylitis Treatment Market Route of Administration Outlook** ### **Ankylosing Spondylitis Treatment Market Patient Type Outlook** ### **Ankylosing Spondylitis Treatment Market Distribution Channel Outlook** ## Market Drivers ### Increased Healthcare Expenditure Rising healthcare expenditure in the US is a significant driver for the ankylosing spondylitis-treatment market. With healthcare spending projected to reach $6 trillion by 2027, there is a growing emphasis on managing chronic conditions such as ankylosing spondylitis. This increase in expenditure allows for greater access to advanced treatment options, including biologics and other innovative therapies. Additionally, insurance coverage for these treatments is improving, which further facilitates patient access. As more patients seek effective management strategies for their condition, the market is expected to expand, potentially leading to a CAGR of around 5% in the coming years. This trend underscores the importance of financial resources in shaping treatment availability. ### Advancements in Treatment Modalities Innovations in treatment modalities are significantly influencing the ankylosing spondylitis-treatment market. The introduction of novel biologic agents and targeted therapies has transformed the landscape of treatment options available to patients. These advancements not only improve patient outcomes but also expand the market by attracting investment from pharmaceutical companies. For instance, the market for biologics is projected to reach approximately $5 billion by 2027, reflecting a growing interest in advanced therapies. Furthermore, the development of personalized medicine approaches may enhance treatment efficacy, thereby increasing patient adherence and satisfaction. As a result, the market is likely to experience sustained growth driven by these advancements. ### Regulatory Support for New Therapies Regulatory support for the approval of new therapies is a critical driver for the ankylosing spondylitis-treatment market. The US Food and Drug Administration (FDA) has been actively facilitating the development and approval of innovative treatments, including biologics and biosimilars. This supportive regulatory environment encourages pharmaceutical companies to invest in research and development, leading to a broader range of treatment options for patients. The expedited approval processes for breakthrough therapies may result in a faster market entry for new products, thereby enhancing competition and potentially lowering treatment costs. As a result, the market is likely to benefit from increased availability of effective therapies, which could drive growth in the coming years. ### Rising Awareness and Education Initiatives The rise in awareness and education initiatives regarding ankylosing spondylitis is a pivotal driver for the ankylosing spondylitis-treatment market. Organizations and healthcare providers are increasingly focusing on educating both patients and healthcare professionals about the disease, its symptoms, and available treatment options. This heightened awareness is likely to lead to earlier diagnosis and treatment, which can significantly improve patient outcomes. As more individuals recognize the importance of seeking treatment, the demand for therapies is expected to rise. Consequently, this trend may contribute to a market growth rate of approximately 4% over the next few years, as more patients engage with healthcare systems for management of their condition. ### Growing Prevalence of Ankylosing Spondylitis The increasing prevalence of ankylosing spondylitis in the US is a crucial driver for the ankylosing spondylitis-treatment market. Recent estimates suggest that approximately 0.1-0.5% of the US population is affected by this condition, leading to a heightened demand for effective treatment options. As awareness of the disease grows, more individuals are seeking medical attention, which in turn drives the market for therapies. The rising number of diagnosed cases is expected to contribute to a compound annual growth rate (CAGR) of around 6% in the treatment market over the next few years. This trend indicates a robust market potential as healthcare providers and pharmaceutical companies focus on developing innovative therapies to address the needs of this patient population. ## Future Outlook The [Ankylosing Spondylitis Treatment Market](https://www.marketresearchfuture.com/reports/ankylosing-spondylitis-treatment-market-12171) is projected to grow at a 4.9% CAGR from 2025 to 2035, driven by advancements in biologics, increasing patient awareness, and enhanced diagnostic tools. **New opportunities:** - Development of personalized biologic therapies for targeted treatment Expansion of telehealth services for remote patient management Investment in AI-driven diagnostic tools for early detection By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Type: Tumor Necrosis Factor Inhibitors (Largest) vs. Interleukin Inhibitors (Fastest-Growing) In the US ankylosing spondylitis-treatment market, the market share distribution among type segments reveals that Tumor Necrosis Factor Inhibitors lead significantly, capturing the largest share due to their established efficacy in managing symptoms. Non-Steroidal Anti-Inflammatory Drugs and Disease Modifying Anti-Rheumatic Drugs follow, contributing to the overall treatment landscape, while Analgesics hold a smaller, yet essential, role for pain management. Interleukin Inhibitors are emerging as noteworthy players due to increasing adoption and recognition in recent years. Growth trends in the segment indicate a promising shift towards biologics, particularly Interleukin Inhibitors, which are noted as the fastest-growing segment. This uptick is fueled by advancements in biotechnology and increasing investments towards innovative therapies that showcase safety and effective symptom control. The rising prevalence of ankylosing spondylitis also drives demand across all types, as healthcare providers seek diverse treatment options for better patient outcomes. Tumor Necrosis Factor Inhibitors (Dominant) vs. Interleukin Inhibitors (Emerging) Tumor Necrosis Factor Inhibitors dominate the US ankylosing spondylitis-treatment market due to longstanding clinical efficacy and a well-established patient base. They are widely prescribed for their ability to alleviate symptoms and improve quality of life, making them the go-to option among rheumatologists. In contrast, Interleukin Inhibitors are emerging as a significant alternative, particularly among patients who do not respond well to traditional therapies. Their novel mechanisms of action and improved safety profiles are leading to increased interest, positioning them as a frontrunner for future growth in the market. The differentiation in treatment approaches between these two segments highlights the ongoing evolution of therapy choices available for ankylosing spondylitis patients. ### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing) In the US ankylosing spondylitis-treatment market, the route of administration segment exhibits a diverse distribution of market share among oral, injectable, and topical treatments. Currently, oral administration leading the segment accounts for a significant share, attributed to its ease of use and patient preference. Injectable options, while smaller in share, are rapidly gaining traction due to advancements in formulation and delivery methods, appealing to a subset of patients that require more intensive medical intervention. Growth trends within the route of administration segment are primarily driven by innovation in drug formulation and a growing emphasis on patient compliance. The rise of biologic therapies and targeted treatments being administered via injection is reshaping the market landscape. Additionally, the increasing incidence of ankylosing spondylitis in the population fosters a progressive shift towards treatments that offer greater efficacy, with injectables emerging as a preferred choice for many patients looking for effective management of their condition. Oral (Dominant) vs. Injectable (Emerging) The oral route of administration remains dominant in the treatment landscape for ankylosing spondylitis, favored for its convenience and non-invasive nature. Oral medications are often the first-line treatment, allowing patients to easily manage their intake at home. In contrast, injectables are quickly becoming an emerging option as they promise faster onset of action and improved efficacy for managing severe symptoms. This shift towards injectable treatments is particularly pronounced among patients seeking rapid relief and who are willing to adopt injectable therapies. As the US ankylosing spondylitis-treatment market evolves, the dynamic between these routes continues to shape patient choices and treatment protocols. ### By Patient Type: Adults (Largest) vs. Pediatric (Fastest-Growing) In the US ankylosing spondylitis-treatment market, the patient type segment is predominantly composed of adults, who hold a significant majority share. This adult demographic has been recognized for its stable demand for treatment options, reflecting the chronic nature of ankylosing spondylitis in this age group. While The pediatric segment is smaller. However, it is gaining traction as awareness of early diagnosis and treatment for young patients increases. The growth trends for this segment indicate a burgeoning interest in pediatric treatment options. As healthcare providers emphasize early intervention, the pediatric segment is projected to expand at a faster rate. Variables driving this growth include increased advocacy for pediatric care, advancements in treatment modalities tailored for younger patients, and a heightened focus on reducing long-term complications through early therapies. Adults (Dominant) vs. Pediatric (Emerging) The adult segment in the US ankylosing spondylitis-treatment market remains dominant due to a well-established routine of monitoring and management within this demographic. Adults typically require a range of treatment options, including biologics and physical therapy, as they are more susceptible to chronic complications. On the other hand, the pediatric segment is emerging, fueled by rising awareness of ankylosing spondylitis among children and adolescents. This segment is characterized by a growing need for specialized treatments and care strategies designed for younger patients, ensuring they receive timely interventions to manage their condition effectively. The success of pediatric treatment options relies on continued research and the development of age-appropriate therapies. ### By Distribution Channel: Hospital Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing) Within the US ankylosing spondylitis-treatment market, the distribution of treatments through channels reveals that Hospital Pharmacy holds the largest market share. This segment is critical due to its comprehensive patient care and direct access to specialist [treatment](../../../reports/thrombus-treatment-market-11453) options. Retail Pharmacy follows, providing significant accessibility, while Online Pharmacy is emerging rapidly, reflecting changing consumer preferences towards convenience and availability. Growth trends indicate a substantial shift towards Online Pharmacy, driven by the increased adoption of e-commerce in healthcare and the demand for at-home treatment options. The Hospital Pharmacy segment remains strong due to the close relationship with healthcare providers and immediate availability of critical medications. This dynamic is reshaping the competitive landscape as patients seek more flexible treatment options. Hospital Pharmacy (Dominant) vs. Online Pharmacy (Emerging) The Hospital Pharmacy segment is characterized by its strong presence in inpatient care settings, offering specialized treatments that are vital for acute cases of ankylosing spondylitis. It plays a dominant role due to its ability to provide immediate access to therapies, often in conjunction with effective monitoring from healthcare professionals. In contrast, Online Pharmacy is rapidly emerging as a preferred option for many patients who value convenience and discretion in managing their health. This segment leverages technological advancements to facilitate seamless ordering and delivery processes, appealing particularly to younger demographics and those facing mobility challenges. ## Competitive Benchmarking The ankylosing spondylitis-treatment market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for effective therapies. Key players such as AbbVie (US), Amgen (US), and Pfizer (US) are actively engaged in innovation and strategic partnerships to enhance their market positions. AbbVie (US) focuses on expanding its portfolio through research and development, particularly in biologics, while Amgen (US) emphasizes the integration of digital health solutions into its treatment offerings. Pfizer (US) is pursuing collaborations with biotechnology firms to leverage cutting-edge technologies, thereby shaping a competitive environment that prioritizes innovation and patient-centric solutions. The market structure appears moderately fragmented, with several players vying for market share. Companies are adopting various business tactics, such as localizing manufacturing and optimizing supply chains, to enhance operational efficiency. This collective influence of key players fosters a competitive atmosphere where agility and responsiveness to market needs are paramount. The presence of multiple stakeholders encourages a diverse range of treatment options, ultimately benefiting patients. In October 2025, AbbVie (US) announced a strategic partnership with a leading digital health company to develop a mobile application aimed at improving patient adherence to treatment regimens. This initiative underscores AbbVie's commitment to integrating technology into patient care, potentially enhancing treatment outcomes and patient engagement. Such collaborations may also position AbbVie favorably in a market increasingly focused on holistic patient management. In September 2025, Pfizer (US) launched a new clinical trial for a novel therapy targeting ankylosing spondylitis, which aims to address unmet medical needs in this patient population. This move reflects Pfizer's strategy to innovate within the therapeutic landscape, potentially expanding its market share by offering cutting-edge solutions. The trial's outcomes could significantly influence treatment protocols and patient access to advanced therapies. In August 2025, Amgen (US) unveiled a new initiative to streamline its supply chain processes, focusing on sustainability and efficiency. This strategic action not only aims to reduce operational costs but also aligns with the growing emphasis on environmentally responsible practices within the pharmaceutical industry. By enhancing supply chain reliability, Amgen may improve its competitive edge in a market where timely access to therapies is critical. As of November 2025, current trends in the ankylosing spondylitis-treatment market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. The evolution of competitive differentiation appears to be moving away from price-based competition towards a focus on technological advancements, innovative treatment solutions, and robust supply chain management. This shift may ultimately redefine how companies position themselves in the market, emphasizing the importance of adaptability and forward-thinking strategies. ## Recent News & Developments The US Ankylosing Spondylitis Treatment Market has recently seen significant developments, particularly surrounding new therapeutic options and competitive strategies among key players like Celgene, Novartis, Takeda, Merck, Eli Lilly, Bristol Myers Squibb, Gilead Sciences, Sandoz, Pfizer, Amgen, AbbVie, Roche, Sanofi, Johnson and Johnson, and UCB. In September 2023, Eli Lilly announced promising results from a clinical trial on a novel monoclonal antibody aimed at improving patient outcomes, indicating strong growth potential for their treatment pipeline. Notably, in July 2023, AbbVie acquired an innovative biotech firm to enhance its Research and Development capabilities in inflammatory diseases, reflecting strategic moves to solidify their market position. Market valuation for Ankylosing Spondylitis treatments is projected to grow significantly, driven by an increasing prevalence of the disease among the US population and advancements in biological therapies. The integration of biosimilars into treatment protocols is also on the rise, as seen with Sandoz and Pfizer, aiming to make treatments more accessible. Over the last few years, robust investment in biologics and targeted therapies has transformed the treatment landscape, aligning with the growing need for effective solutions in managing Ankylosing Spondylitis. ## Report Scope | MARKET SIZE 2024 | 1211.62(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1270.99(USD Million) | | MARKET SIZE 2035 | 2051.07(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Novartis (CH), Pfizer (US), Roche (CH), Sanofi (FR), UCB (BE) | | Segments Covered | Type, Route of Administration, Patient Type, Distribution Channel | | Key Market Opportunities | Advancements in biologics and personalized medicine enhance treatment options in the ankylosing spondylitis-treatment market. | | Key Market Dynamics | Rising demand for biologics drives innovation and competition in the ankylosing spondylitis-treatment market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US ankylosing spondylitis-treatment market in 2024?** A: The market valuation was $1211.62 Million in 2024. **Q: What is the projected market valuation for the US ankylosing spondylitis-treatment market by 2035?** A: The projected valuation for 2035 is $2051.07 Million. **Q: What is the expected CAGR for the US ankylosing spondylitis-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 4.9%. **Q: Which segment had the highest valuation in the US ankylosing spondylitis-treatment market in 2024?** A: The segment of Tumor Necrosis Factor Inhibitors had a valuation of $400.0 - $700.0 Million in 2024. **Q: What are the key players in the US ankylosing spondylitis-treatment market?** A: Key players include AbbVie, Amgen, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Roche, Sanofi, and UCB. **Q: What was the valuation range for Non-Steroidal Anti-Inflammatory Drugs in 2024?** A: The valuation range for Non-Steroidal Anti-Inflammatory Drugs was $300.0 - $500.0 Million in 2024. **Q: How does the valuation of Injectable treatments compare to Oral treatments in 2024?** A: Injectable treatments had a valuation range of $600.0 - $1000.0 Million, significantly higher than Oral treatments, which ranged from $300.0 - $500.0 Million. **Q: What was the valuation for the Pediatric patient type segment in 2024?** A: The valuation for the Pediatric patient type segment was $211.62 - $351.07 Million in 2024. **Q: Which distribution channel had the highest valuation in 2024?** A: The Retail Pharmacy distribution channel had a valuation range of $500.0 - $800.0 Million in 2024. **Q: What is the projected growth trend for the US ankylosing spondylitis-treatment market?** A: The market is expected to grow steadily, reaching $2051.07 Million by 2035, indicating a robust growth trend. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-ankylosing-spondylitis-treatment-market-15874*